Aetna · Identified Aug 18, 2026Medium impact
Vocal Cord Paralysis / Insufficiency Treatments (CPB 0253, reviewed 2026-04-15)
Aetna Clinical Policy Bulletin 0253 addresses treatments for vocal cord paralysis and insufficiency. Aetna considers medically necessary injections of bulking agents for members with unilateral vocal cord paralysis when the agent is cleared by the FDA for this indication, medialization thyroplasty (type 1 thyroplasty), medialization laryngoplasty with arytenoid adduction, steroid injection after microsurgical removal of vocal fold lesions, Radiesse, autologous fat, Cymetra or Restylane when unilateral paralysis is anticipated to be short-term, laryngeal electromyography, and interarytenoid augmentation with an injectable filler for posterior laryngeal clefts in infants after a 3-month trial of conservative management has failed. Botulinum toxin injection for vocal cord paralysis, Deflux for velopharyngeal insufficiency, basic fibroblast growth factor, Juvederm, laryngeal reinnervation, posterior cricoarytenoideus re-innervation and pacing, injections of bulking agents for indications other than those listed as medically necessary, and transcutaneous laryngeal ultrasound for evaluation of hyaluronic acid status after injection laryngoplasty are considered experimental, investigational or unproven.